Newswise — Hackensack University Medical Center is the only site in New Jersey that is participating in the ROADSTER 3 clinical trial to assess real-world outcomes for patients with carotid artery disease who have an average surgical risk and undergo a minimally invasive surgical procedure called transcarotid artery revascularization (TCAR).
TCAR is a minimally invasive procedure that allows vascular surgeons to more safely treat blockages caused by plaque inside the carotid arteries, which are located on either side of the neck and supply blood to the brain. Blockages in the carotid artery are associated with an increased risk of stroke, and are responsible for a third of all strokes in the U.S.
During TCAR, surgeons access the carotid artery through a small incision in the patient’s neck just above the collarbone and insert a specialized sheath to deliver a stent that unblocks the carotid artery. The sheath temporarily reverses blood flow in the carotid artery so that it travels away from the brain, preventing small pieces of plaque that may break off during the procedure from moving to the brain where they could cause a stroke.
A Safer Alternative to Traditional Carotid Artery Revascularization Procedures
TCAR is an alternative to an open procedure called a carotid endarterectomy and another minimally invasive procedure called transfemoral filter-protected stenting, both of which can carry a higher risk of stroke than the TCAR procedure. In addition to reducing the risk of a procedural stroke, another benefit is that TCAR is typically performed through a small incision near the treatment site using local anesthesia and light sedation — making it an ideal option for patients who may be at high risk of complications related to general anesthesia or a more invasive procedure.
“Initially, TCAR was only approved for patients with carotid artery disease who were at high risk of experiencing surgical complications due to age, other medical conditions, or complex anatomy — and TCAR has delivered excellent outcomes in those patients,” said David O’Connor, M.D., FACS, Director of Vascular Research at Hackensack University Medical Center and Assistant Professor of Surgery at Hackensack Meridian School of Medicine. “Through the ROADSTER 3 trial, we are looking at the benefits of TCAR for patients with a standard surgical risk with the goal of expanding our ability to offer this procedure to a majority of patients with carotid artery disease.”
Nationally Recognized for TCAR Experience and Excellence
Under Dr. O’Connor’s leadership, Hackensack University Medical Center is the highest-volume TCAR center in New Jersey and among the highest-volume centers in the region. Additionally, Hackensack University Medical Center has been named a TCAR Center of Excellence by Silk Road Medical, the company that developed the TCAR procedure.
Hackensack Meridian Health was one of the first health networks in New Jersey to offer TCAR, performing more than 100 TCAR procedures since the technique and technology became available in 2017. As a result, Hackensack Meridian Health vascular surgeons are among the most experienced in the region at performing TCAR and receive prestigious invitations to participate in groundbreaking prospective national multi-center clinical trials such as ROADSTER 3.
Dr. O’Connor has also published research on TCAR and has served as a proctor for the TCAR procedure, providing TCAR training to vascular surgeons across the nation.
Dr. O’Connor and his team at Hackensack University Medical Center were recently featured in a segment on News 12 New Jersey highlighting the hospital’s 100th TCAR milestone. The team hopes that this coverage will raise awareness about minimally invasive treatment options for carotid artery disease.
“Patients who are at risk for other types of heart disease due to smoking, high cholesterol, high blood pressure, diabetes, and a personal or family history of heart disease, should also be screened for carotid artery disease,” said Dr. O’Connor. “We want people in our communities to know that safe treatment is available for carotid artery disease that can reduce stroke risk.”
ABOUT HACKENSACK UNIVERSITY MEDICAL CENTER
Hackensack University Medical Center, a 803-bed nonprofit teaching and research hospital, was Bergen County’s first hospital founded in 1888. It was also the first hospital in New Jersey and second in the nation to become a Magnet®-recognized hospital for nursing excellence, receiving its sixth consecutive designation from the American Nurses Credentialing Center. The academic flagship of the Hackensack Meridian Health network, Hackensack University Medical Center is Nationally-Ranked by U.S. News & World Report 2022-2023 in four specialties, more than any other hospital in New Jersey. The hospital is home to the state's only nationally-ranked Urology and Neurology & Neurosurgery programs, as well as the best Cardiology & Heart Surgery program. It also offers patients nationally-ranked Orthopedic care and one of the state’s premier Cancer Centers (John Theurer Cancer Center at Hackensack University Medical Center). Hackensack University Medical Center also ranked as High-Performing in conditions such as Acute Kidney Failure, Heart Attack (AMI), Heart Failure, Pneumonia, chronic obstructive pulmonary disease (COPD), Diabetes and Stroke. As well as High Performing in procedures like Aortic Valve Surgery, Heart Bypass Surgery (CABG), Colon Cancer Surgery, Lung Cancer Surgery, Prostate Cancer Surgery, Hip Replacement and Knee Replacement. Named to Newsweek’s World’s Best Hospitals 2023 list, Hackensack University Medical Center is also the recipient of the 2023 Patient Safety Excellence Award™ by Healthgrades as well as an “A” Hospital Safety Grade from The Leapfrog Group. This award-winning care is provided on a campus that is home to facilities such as the Heart & Vascular Hospital; and the Sarkis and Siran Gabrellian Women’s and Children’s Pavilion, which houses the Donna A. Sanzari Women’s Hospital and the Joseph M. Sanzari Children’s Hospital, ranked #1 in the state and top 20 in the Mid-Atlantic Region in the U.S. News & World Report’s 2022-23 Best Children’s Hospital Report. Additionally, the children’s nephrology program ranks in the top 50 in the United States. Hackensack University Medical Center is also home to the Deirdre Imus Environmental Health Center and is listed on the Green Guide’s list of Top 10 Green Hospitals in the U.S. Our comprehensive clinical research portfolio includes studies focused on precision medicine, translational medicine, immunotherapy, cell therapy, and vaccine development. The hospital has embarked on the largest healthcare expansion project ever approved by the state: Construction of the Helena Theurer Pavilion, a 530,000-sq.-ft., nine-story building, which began in 2019. A $714.2 million endeavor, the pavilion is one the largest healthcare capital projects in New Jersey and will house 24 state-of-the-art operating rooms with intraoperative MRI capability, 50 ICU beds, and 175 medical/surgical beds including a 50 room Musculoskeletal Institute.
RSS